OTCMKTS:IPHYF Innate Pharma (IPHYF) Stock Price, News & Analysis $1.51 0.00 (0.00%) As of 10/12/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsNews and TrendsSEC FilingsShort Interest About Innate Pharma Stock (OTCMKTS:IPHYF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Innate Pharma alerts:Sign Up Key Stats Today's Range$1.51▼$1.5150-Day Range$1.51▼$1.6552-Week Range$1.37▼$2.25VolumeN/AAverage Volume50 shsMarket Capitalization$126.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Innate Pharma S.A. is a France-based biotechnology company focused on developing immunotherapies for cancer. The company’s research is centered on the biology of the innate immune system, including natural killer cells and other immune cells that can recognize and attack tumor cells. Innate Pharma develops therapeutic antibodies and related immune-oncology approaches. Its pipeline has included lacutamab, an antibody being studied in certain types of cutaneous T-cell lymphoma, as well as investigational programs designed to activate or engage natural killer cells. The company has also advanced monalizumab, an immune checkpoint antibody, through collaborations with larger pharmaceutical companies. Founded in 1999 and headquartered in Marseille, France, Innate Pharma conducts research and clinical-development activities through international collaborations and studies. The company’s programs have been evaluated in multiple geographic regions, including Europe and North America. Mondher Mahjoubi serves as chief executive officer.AI Generated. May Contain Errors. Read More Receive IPHYF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IPHYF Stock News HeadlinesInnate Pharma consensus price target raised by 29.07% to 7,10 €October 3, 2026 | msn.comConsensus price target for Innate Pharma increases 23.99% to €6.77October 2, 2026 | msn.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 14 at 1:00 AM | Weiss Ratings (Ad)Sobi partnership with Innate Pharma takes effectSeptember 17, 2026 | marketscreener.comMInnate Pharma Secures Sobi Partnership Cash and Extends Runway as Key Oncology Trials AdvanceSeptember 17, 2026 | tipranks.comInnate Pharma to deliver H1 2026 business update via investor webcastSeptember 10, 2026 | tipranks.comInnate Pharma to Highlight Oncology Pipeline at H.C. Wainwright Investment ConferenceSeptember 2, 2026 | tipranks.comInnate Pharma to Spotlight Oncology Pipeline at H.C. Wainwright Investor ConferenceSeptember 2, 2026 | tipranks.comSee More Headlines IPHYF Stock Analysis - Frequently Asked Questions How have IPHYF shares performed this year? Innate Pharma's stock was trading at $2.1550 at the beginning of the year. Since then, IPHYF stock has decreased by 30.0% and is now trading at $1.5092. How do I buy shares of Innate Pharma? Shares of IPHYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Innate Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Innate Pharma investors own include Cellectis (CLLS), Redhill Biopharma (RDHL), Adocia (ADOCY), Advanced Oxygen Technologies (AOXY), Aixtron (AIXA), Aareal Bank (ARL) and Arbutus Biopharma (ABUS). Company Calendar Today10/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:IPHYF Previous SymbolNASDAQ:IPHYF CIK1598599 Webwww.innate-pharma.com Phone(343) 030-3030Fax33-04-30-30-30-00Employees163Year Founded1999Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$10.19 million Price / Sales12.42 Cash FlowN/A Price / Cash FlowN/A Book Value($0.29) per share Price / Book-5.20Miscellaneous Outstanding Shares83,830,000Free Float57,097,000Market Cap$126.52 million OptionableNot Optionable Beta0.65 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:IPHYF) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredMy next big call (under $1)The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a...Crypto 101 Media | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma SA Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
